The launch time and progress of Telisotuzumab in China

Telisotuzumab (Telisotuzumab) is an antibody-conjugated drug ( ADC), mainly used to treat patients with non-small cell lung cancer (NSCLC) with high expression of TROP2. As a new generation of targeted therapy drugs, terituzumab specifically binds to the TROP2 receptor on the surface of tumor cells and accurately delivers cytotoxic drugs into cancer cells, thereby exerting anti-tumor effects. At present, the drug has shown good efficacy and safety in multiple international clinical trials and has received widespread attention from the industry.

As of2025, terituzumab has not yet been officially approved for marketing in China. The domestic registration and approval of drugs is still in progress and is still in clinical trial preparation or early stages. Since there is no relevant clinical research data in China, the clinical application and market promotion of this drug in China still takes time. Patients currently cannot obtain the drug through formal medical channels, and related treatments mostly rely on overseas clinical trials or special channels.

The international clinical development of Terituzumab is progressing rapidly, and many countries and regions are conducting Phase II and Phase III clinical trials to evaluate its efficacy and safety in advanced NSCLC and other solid tumors. As clinical data continues to accumulate, the drug is expected to be approved by more countries and enter more markets in the next few years. China's drug regulatory authorities have a positive attitude towards innovative anti-cancer drugs, and it is expected that terituzumab will obtain marketing authorization in China in the near future.

For patients and doctors who are concerned about territuzumab, it is recommended to continue to pay attention to the latest information released by the National Food and Drug Administration (NMPA) and relevant pharmaceutical companies. While waiting for the drug to be launched, patients should follow the doctor's advice to choose an appropriate treatment plan and avoid blindly purchasing drugs from informal channels to ensure the safety of treatment. With the progress of approval and the emergence of more clinical evidence, terituzumab is expected to bring new hope to Chinese patients with non-small cell lung cancer.

Reference materials:https://www.drugs.com/